CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • First Checkpoint Immunotherapy Approved for Advanced Cervical Cancer

    Pembrolizumab, a PD-1-targeting immunotherapy, was approved for recurrent advanced cervical cancer that expresses PD-L1.

    June 13, 2018| Arthur N. Brodsky, PhD
  • Second CAR T Cell Immunotherapy Approved for Patients with Lymphoma

    A second CAR T cell immunotherapy targeting the CD19 receptor was approved by the FDA for patients…

    May 3, 2018| Arthur N. Brodsky, PhD
  • AACR18 Recap: Immunotherapy in the Spotlight

    Immunotherapy took center stage and dominated the headlines at AACR18.

    April 23, 2018| Arthur N. Brodsky, PhD
  • Checkpoint Immunotherapy Combination Approved for First-line Treatment of Advanced Kidney Cancer

    The combination of checkpoint immunotherapies against PD-1 and CTLA-4 significantly improved survival and response rates compared to…

    April 16, 2018| Arthur N. Brodsky, PhD
  • Immunotherapy is Here to Stay: Looking Back at this Year’s Breakthroughs

    Important immunotherapy breakthroughs benefited patients immensely in 2017 and paved the way for even more advances in…

    December 28, 2017| Arthur N. Brodsky, PhD
  • Recent FDA Announcements Herald Advances in Personalized Approaches Against Cancer

    Two tumor-profiling tests recently authorized by the FDA enable doctors to tailor their treatments more effectively to…

    December 22, 2017| Arthur N. Brodsky, PhD
  • CAR T Cell Immunotherapy Approved for Adult Non-Hodgkin Lymphoma Patients

    FDA approves new immunotherapy–Yescarta (axicabtagene ciloleucel)–for adult patients with relapsed or refractory non-Hodgkin large B cell lymphoma.

    October 18, 2017| Arthur N. Brodsky, PhD
  • Checkpoint Immunotherapy Approved for Patients with Stomach, Gastroesophageal, and Liver Cancer

    Previously treated patients with these cancer types can now receive anti-PD-1 immunotherapy; nivolumab for HCC and pembrolizumab…

    September 25, 2017| Arthur N. Brodsky, PhD
  • FDA Approves First-In-Class CAR T Cell Immunotherapy for Leukemia

    Children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) can now receive the CD19-targeting CAR T…

    August 30, 2017| Arthur N. Brodsky, PhD
Previous Page
1 2 3 4 5
Next Page

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute